Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome

Thomas E. Neumann, Judith Allanson, Ines Kavamura, Bronwyn Kerr, Giovanni Neri, Jacqueline Noonan, Viviana Cordeddu, Kate Gibson, Andreas Tzschach, Gabriele Krüger, Maria Hoeltzenbein, Timm O. Goecke, Hans Gerd Kehl, Beate Albrecht, Klaudiusz Luczak, Maria M. Sasiadek, Luciana Musante, Rohan Laurie, Hartmut Peters, Marco TartagliaMartin Zenker, Vera Kalscheuer

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS) are related developmental disorders caused by mutations in genes encoding various components of the RAS-MAPK signaling cascade. NS is associated with mutations in the genes PTPN11, SOS1, RAF1, or KRAS, whereas CFCS can be caused by mutations in BRAF, MEK1, MEK2, or KRAS. The NS phenotype is rarely accompanied by multiple giant cell lesions (MGCL) of the jaw (Noonan-like/MGCL syndrome (NL/MGCLS)). PTPN11 mutations are the only genetic abnormalities reported so far in some patients with NL/ MGCLS and in one individual with LEOPARD syndrome and MGCL. In a cohort of 75 NS patients previously tested negative for mutations in PTPN11 and KRAS, we detected SOS1 mutations in 11 individuals, four of whom had MGCL. To explore further the relevance of aberrant RAS-MAPK signaling in syndromic MGCL, we analyzed the established genes causing CFCS in three subjects with MGCL associated with a phenotype fitting CFCS. Mutations in BRAF or MEK1 were identified in these patients. All mutations detected in these seven patients with syndromic MGCL had previously been described in NS or CFCS without apparent MGCL. This study demonstrates that MGCL may occur in NS and CFCS with various underlying genetic alterations and no obvious genotype-phenotype correlation. This suggests that dysregulation of the RAS-MAPK pathway represents the common and basic molecular event predisposing to giant cell lesion formation in patients with NS and CFCS rather than specific mutation effects.

Original languageEnglish
Pages (from-to)420-425
Number of pages6
JournalEuropean Journal of Human Genetics
Volume17
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

Noonan Syndrome
Giant Cells
Mutation
LEOPARD Syndrome
Genes
Phenotype
Cardiofaciocutaneous syndrome
Genetic Association Studies
Jaw

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Neumann, T. E., Allanson, J., Kavamura, I., Kerr, B., Neri, G., Noonan, J., ... Kalscheuer, V. (2009). Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. European Journal of Human Genetics, 17(4), 420-425. https://doi.org/10.1038/ejhg.2008.188

Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. / Neumann, Thomas E.; Allanson, Judith; Kavamura, Ines; Kerr, Bronwyn; Neri, Giovanni; Noonan, Jacqueline; Cordeddu, Viviana; Gibson, Kate; Tzschach, Andreas; Krüger, Gabriele; Hoeltzenbein, Maria; Goecke, Timm O.; Kehl, Hans Gerd; Albrecht, Beate; Luczak, Klaudiusz; Sasiadek, Maria M.; Musante, Luciana; Laurie, Rohan; Peters, Hartmut; Tartaglia, Marco; Zenker, Martin; Kalscheuer, Vera.

In: European Journal of Human Genetics, Vol. 17, No. 4, 2009, p. 420-425.

Research output: Contribution to journalArticle

Neumann, TE, Allanson, J, Kavamura, I, Kerr, B, Neri, G, Noonan, J, Cordeddu, V, Gibson, K, Tzschach, A, Krüger, G, Hoeltzenbein, M, Goecke, TO, Kehl, HG, Albrecht, B, Luczak, K, Sasiadek, MM, Musante, L, Laurie, R, Peters, H, Tartaglia, M, Zenker, M & Kalscheuer, V 2009, 'Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome', European Journal of Human Genetics, vol. 17, no. 4, pp. 420-425. https://doi.org/10.1038/ejhg.2008.188
Neumann, Thomas E. ; Allanson, Judith ; Kavamura, Ines ; Kerr, Bronwyn ; Neri, Giovanni ; Noonan, Jacqueline ; Cordeddu, Viviana ; Gibson, Kate ; Tzschach, Andreas ; Krüger, Gabriele ; Hoeltzenbein, Maria ; Goecke, Timm O. ; Kehl, Hans Gerd ; Albrecht, Beate ; Luczak, Klaudiusz ; Sasiadek, Maria M. ; Musante, Luciana ; Laurie, Rohan ; Peters, Hartmut ; Tartaglia, Marco ; Zenker, Martin ; Kalscheuer, Vera. / Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. In: European Journal of Human Genetics. 2009 ; Vol. 17, No. 4. pp. 420-425.
@article{6db7d6bc934041a0bc4196805c1b8e4c,
title = "Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome",
abstract = "Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS) are related developmental disorders caused by mutations in genes encoding various components of the RAS-MAPK signaling cascade. NS is associated with mutations in the genes PTPN11, SOS1, RAF1, or KRAS, whereas CFCS can be caused by mutations in BRAF, MEK1, MEK2, or KRAS. The NS phenotype is rarely accompanied by multiple giant cell lesions (MGCL) of the jaw (Noonan-like/MGCL syndrome (NL/MGCLS)). PTPN11 mutations are the only genetic abnormalities reported so far in some patients with NL/ MGCLS and in one individual with LEOPARD syndrome and MGCL. In a cohort of 75 NS patients previously tested negative for mutations in PTPN11 and KRAS, we detected SOS1 mutations in 11 individuals, four of whom had MGCL. To explore further the relevance of aberrant RAS-MAPK signaling in syndromic MGCL, we analyzed the established genes causing CFCS in three subjects with MGCL associated with a phenotype fitting CFCS. Mutations in BRAF or MEK1 were identified in these patients. All mutations detected in these seven patients with syndromic MGCL had previously been described in NS or CFCS without apparent MGCL. This study demonstrates that MGCL may occur in NS and CFCS with various underlying genetic alterations and no obvious genotype-phenotype correlation. This suggests that dysregulation of the RAS-MAPK pathway represents the common and basic molecular event predisposing to giant cell lesion formation in patients with NS and CFCS rather than specific mutation effects.",
author = "Neumann, {Thomas E.} and Judith Allanson and Ines Kavamura and Bronwyn Kerr and Giovanni Neri and Jacqueline Noonan and Viviana Cordeddu and Kate Gibson and Andreas Tzschach and Gabriele Kr{\"u}ger and Maria Hoeltzenbein and Goecke, {Timm O.} and Kehl, {Hans Gerd} and Beate Albrecht and Klaudiusz Luczak and Sasiadek, {Maria M.} and Luciana Musante and Rohan Laurie and Hartmut Peters and Marco Tartaglia and Martin Zenker and Vera Kalscheuer",
year = "2009",
doi = "10.1038/ejhg.2008.188",
language = "English",
volume = "17",
pages = "420--425",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome

AU - Neumann, Thomas E.

AU - Allanson, Judith

AU - Kavamura, Ines

AU - Kerr, Bronwyn

AU - Neri, Giovanni

AU - Noonan, Jacqueline

AU - Cordeddu, Viviana

AU - Gibson, Kate

AU - Tzschach, Andreas

AU - Krüger, Gabriele

AU - Hoeltzenbein, Maria

AU - Goecke, Timm O.

AU - Kehl, Hans Gerd

AU - Albrecht, Beate

AU - Luczak, Klaudiusz

AU - Sasiadek, Maria M.

AU - Musante, Luciana

AU - Laurie, Rohan

AU - Peters, Hartmut

AU - Tartaglia, Marco

AU - Zenker, Martin

AU - Kalscheuer, Vera

PY - 2009

Y1 - 2009

N2 - Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS) are related developmental disorders caused by mutations in genes encoding various components of the RAS-MAPK signaling cascade. NS is associated with mutations in the genes PTPN11, SOS1, RAF1, or KRAS, whereas CFCS can be caused by mutations in BRAF, MEK1, MEK2, or KRAS. The NS phenotype is rarely accompanied by multiple giant cell lesions (MGCL) of the jaw (Noonan-like/MGCL syndrome (NL/MGCLS)). PTPN11 mutations are the only genetic abnormalities reported so far in some patients with NL/ MGCLS and in one individual with LEOPARD syndrome and MGCL. In a cohort of 75 NS patients previously tested negative for mutations in PTPN11 and KRAS, we detected SOS1 mutations in 11 individuals, four of whom had MGCL. To explore further the relevance of aberrant RAS-MAPK signaling in syndromic MGCL, we analyzed the established genes causing CFCS in three subjects with MGCL associated with a phenotype fitting CFCS. Mutations in BRAF or MEK1 were identified in these patients. All mutations detected in these seven patients with syndromic MGCL had previously been described in NS or CFCS without apparent MGCL. This study demonstrates that MGCL may occur in NS and CFCS with various underlying genetic alterations and no obvious genotype-phenotype correlation. This suggests that dysregulation of the RAS-MAPK pathway represents the common and basic molecular event predisposing to giant cell lesion formation in patients with NS and CFCS rather than specific mutation effects.

AB - Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS) are related developmental disorders caused by mutations in genes encoding various components of the RAS-MAPK signaling cascade. NS is associated with mutations in the genes PTPN11, SOS1, RAF1, or KRAS, whereas CFCS can be caused by mutations in BRAF, MEK1, MEK2, or KRAS. The NS phenotype is rarely accompanied by multiple giant cell lesions (MGCL) of the jaw (Noonan-like/MGCL syndrome (NL/MGCLS)). PTPN11 mutations are the only genetic abnormalities reported so far in some patients with NL/ MGCLS and in one individual with LEOPARD syndrome and MGCL. In a cohort of 75 NS patients previously tested negative for mutations in PTPN11 and KRAS, we detected SOS1 mutations in 11 individuals, four of whom had MGCL. To explore further the relevance of aberrant RAS-MAPK signaling in syndromic MGCL, we analyzed the established genes causing CFCS in three subjects with MGCL associated with a phenotype fitting CFCS. Mutations in BRAF or MEK1 were identified in these patients. All mutations detected in these seven patients with syndromic MGCL had previously been described in NS or CFCS without apparent MGCL. This study demonstrates that MGCL may occur in NS and CFCS with various underlying genetic alterations and no obvious genotype-phenotype correlation. This suggests that dysregulation of the RAS-MAPK pathway represents the common and basic molecular event predisposing to giant cell lesion formation in patients with NS and CFCS rather than specific mutation effects.

UR - http://www.scopus.com/inward/record.url?scp=62849124342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62849124342&partnerID=8YFLogxK

U2 - 10.1038/ejhg.2008.188

DO - 10.1038/ejhg.2008.188

M3 - Article

C2 - 18854871

AN - SCOPUS:62849124342

VL - 17

SP - 420

EP - 425

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 4

ER -